azathioprine has been researched along with Cardiovascular Diseases in 28 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our experience with azathioprine in the treatment of rheumatoid arthritis covers ten years, during which 91 rheumatoid patients (66 female and 25 male) received this drug, with a median treatment period of 36 months." | 7.66 | Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience. ( Boerbooms, AM; Kruijsen, MW; Speerstra, F; van Beusekom, HJ; van de Putte, LB; Vandenbroucke, JP, 1982) |
| " In addition, the long-term results of the ALMS study have demonstrated that mycophenolate mofetil is superior to azathioprine in maintaining the remission in patients with severe lupus nephritis." | 3.78 | [Allergo-immunology. Clinical immunology]. ( Chizzolini, C, 2012) |
| "Our experience with azathioprine in the treatment of rheumatoid arthritis covers ten years, during which 91 rheumatoid patients (66 female and 25 male) received this drug, with a median treatment period of 36 months." | 3.66 | Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience. ( Boerbooms, AM; Kruijsen, MW; Speerstra, F; van Beusekom, HJ; van de Putte, LB; Vandenbroucke, JP, 1982) |
| "Everolimus is a potent immunosuppressive agent that has anti-proliferative activity." | 2.72 | Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation. ( Eisen, H, 2006) |
| " These studies provide a compelling case for a re-evaluation of the long-term use of glucocorticoids in SLE, focusing on minimizing glucocorticoid exposure as part of the strategy to improve long-term outcomes." | 2.55 | It hasn't gone away: the problem of glucocorticoid use in lupus remains. ( Apostolopoulos, D; Morand, EF, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (14.29) | 18.7374 |
| 1990's | 6 (21.43) | 18.2507 |
| 2000's | 7 (25.00) | 29.6817 |
| 2010's | 8 (28.57) | 24.3611 |
| 2020's | 3 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Fanouriakis, A | 1 |
| Tziolos, N | 1 |
| Bertsias, G | 1 |
| Boumpas, DT | 1 |
| Choi, MY | 1 |
| Li, D | 1 |
| Feldman, CH | 1 |
| Yoshida, K | 1 |
| Guan, H | 1 |
| Kim, SC | 1 |
| Everett, BM | 1 |
| Costenbader, KH | 1 |
| Lorenzo-Vizcaya, A | 1 |
| Isenberg, D | 1 |
| Wallace, ZS | 1 |
| Fu, X | 1 |
| Liao, K | 1 |
| Kallenberg, CGM | 1 |
| Langford, CA | 1 |
| Merkel, PA | 1 |
| Monach, P | 1 |
| Seo, P | 1 |
| Specks, U | 1 |
| Spiera, R | 1 |
| St Clair, EW | 1 |
| Zhang, Y | 1 |
| Choi, H | 1 |
| Stone, JH | 1 |
| Haris, Á | 1 |
| Polner, K | 1 |
| Arányi, J | 1 |
| Braunitzer, H | 1 |
| Kaszás, I | 1 |
| Mucsi, I | 1 |
| Magalhães-Costa, P | 1 |
| Lebre, L | 1 |
| Machado, D | 1 |
| Chagas, C | 1 |
| Thapa, SD | 1 |
| Hadid, H | 1 |
| Schairer, J | 1 |
| Imam, W | 1 |
| Jafri, SM | 1 |
| dos Santos, LC | 1 |
| Costa, AV | 1 |
| Lopes, LG | 1 |
| Leonel, AJ | 1 |
| Aguilar, EC | 1 |
| Noviello, Mde L | 1 |
| Ferrari, Mde L | 1 |
| Alvarez-Leite, JI | 1 |
| Apostolopoulos, D | 1 |
| Morand, EF | 1 |
| Vacher-Coponat, H | 1 |
| Moal, V | 1 |
| Indreies, M | 1 |
| Purgus, R | 1 |
| Loundou, A | 1 |
| Burtey, S | 1 |
| Brunet, P | 1 |
| Moussi-Frances, J | 1 |
| Daniel, L | 1 |
| Dussol, B | 1 |
| Berland, Y | 1 |
| Chizzolini, C | 1 |
| Bakker, RC | 1 |
| Hollander, AA | 1 |
| Mallat, MJ | 1 |
| Bruijn, JA | 1 |
| Paul, LC | 3 |
| de Fijter, JW | 1 |
| Perry, I | 1 |
| Neuberger, J | 1 |
| Kotyla, PJ | 1 |
| Sliwińska-Kotyla, B | 1 |
| Lewicki, M | 1 |
| Kucharz, EJ | 1 |
| Eisen, H | 1 |
| Joss, N | 1 |
| Rodger, RS | 2 |
| McMillan, MA | 2 |
| Junor, BJ | 2 |
| Cheung, CY | 1 |
| Liu, YL | 1 |
| Wong, KM | 1 |
| Chan, HW | 1 |
| Chan, YH | 1 |
| Wong, HS | 1 |
| Chak, WL | 1 |
| Choi, KS | 1 |
| Chau, KF | 1 |
| Shek, CC | 1 |
| Li, CS | 1 |
| Peter, S | 1 |
| Keusch, G | 1 |
| Binswanger, U | 1 |
| Speerstra, F | 1 |
| Boerbooms, AM | 1 |
| van de Putte, LB | 1 |
| van Beusekom, HJ | 1 |
| Kruijsen, MW | 1 |
| Vandenbroucke, JP | 1 |
| Kronenberg, F | 1 |
| Königsrainer, A | 1 |
| Lhotta, K | 1 |
| Margreiter, R | 1 |
| Dieplinger, H | 1 |
| König, P | 1 |
| Steinhäuslin, F | 1 |
| Sutherland, F | 2 |
| Burgess, E | 2 |
| Klassen, J | 2 |
| Buckle, S | 2 |
| Kasiske, BL | 1 |
| MacPhee, IA | 1 |
| Bradley, JA | 1 |
| Briggs, JD | 1 |
| MacPherson, SG | 1 |
| Watson, MA | 1 |
| Hall, RL | 1 |
| Leahy, MF | 1 |
| Gruber, SA | 1 |
| Pescovitz, M | 1 |
| Simmons, RL | 1 |
| Najarian, JS | 1 |
| Ascher, NL | 1 |
| Payne, WD | 1 |
| Sutherland, DE | 1 |
| Elick, B | 1 |
| Fryd, DS | 1 |
| Merrill, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033] | 120 participants (Anticipated) | Interventional | 2022-08-15 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for azathioprine and Cardiovascular Diseases
| Article | Year |
|---|---|
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc | 2021 |
It hasn't gone away: the problem of glucocorticoid use in lupus remains.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cata | 2017 |
Immunosuppression: towards a logical approach in liver transplantation.
Topics: Adrenal Cortex Hormones; Algorithms; Antibodies, Monoclonal; Azathioprine; Calcineurin Inhibitors; C | 2005 |
[Risk of atherosclerosis development in patients with systemic lupus erythematosus].
Topics: Adrenal Cortex Hormones; Arteriosclerosis; Autoantibodies; Azathioprine; Blood Coagulation Disorders | 2005 |
Present status of kidney transplantation.
Topics: Antigen-Antibody Reactions; Antilymphocyte Serum; Azathioprine; B-Lymphocytes; Bone Diseases; Cardio | 1974 |
8 trials available for azathioprine and Cardiovascular Diseases
| Article | Year |
|---|---|
A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Topics: Adult; Antilymphocyte Serum; Azathioprine; Cardiovascular Diseases; Cohort Studies; Cyclosporine; Dr | 2012 |
Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy.
Topics: Adult; Azathioprine; Biopsy; Cardiovascular Diseases; Cause of Death; Chronic Disease; Cyclosporine; | 2003 |
Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
Topics: Azathioprine; Cardiovascular Diseases; Cyclosporine; Dose-Response Relationship, Drug; Double-Blind | 2006 |
Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
Topics: Adult; Azathioprine; Cardiovascular Diseases; Cause of Death; Cyclosporine; Follow-Up Studies; Human | 2007 |
Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Human | 2008 |
[Treatment of chronic kidney failure in diabetes mellitus].
Topics: Adult; Azathioprine; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetic Nephropathies; Dia | 1983 |
Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation.
Topics: Acute Disease; Adolescent; Adult; Aged; Azathioprine; Blood Pressure; Cardiovascular Diseases; Cyclo | 1998 |
Thromboembolic complications after renal transplantation: results from the randomized trial of cyclosporine v azathioprine-antilymphocyte globulin.
Topics: Antilymphocyte Serum; Azathioprine; Cardiovascular Diseases; Cyclosporins; Humans; Kidney Transplant | 1987 |
15 other studies available for azathioprine and Cardiovascular Diseases
| Article | Year |
|---|---|
Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications.
Topics: Adult; Azathioprine; Cardiovascular Diseases; Cause of Death; Coronary Artery Bypass; Cyclophosphami | 2021 |
Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom.
Topics: Adult; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cause of Death; Cohort Studies; | 2021 |
Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil | 2019 |
Clinical outcomes of ANCA-associated vasculitis in elderly patients.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculi | 2014 |
Lack of impact of hepatitis C virus infection on graft survival after kidney transplantation--a Portuguese single-center experience.
Topics: Adult; Age Factors; Aged; Azathioprine; Cardiovascular Diseases; Case-Control Studies; Cyclosporine; | 2015 |
Effect of Inflammatory Bowel Disease-Related Characteristics and Treatment Interventions on Cardiovascular Disease Incidence.
Topics: Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Cardiovascular Diseases; Case-Control Studies; | 2015 |
Combination of Azathioprine and Aminosalicylate Treatment Prevent Risk of Cardiovascular Disease in Women with Ulcerative Colitis by Reducing Inflammation.
Topics: Adult; Aminosalicylic Acid; Azathioprine; Biomarkers; Cardiovascular Diseases; Case-Control Studies; | 2015 |
[Allergo-immunology. Clinical immunology].
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal; Antibodies, Mono | 2012 |
Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience.
Topics: Aged; Arthritis, Rheumatoid; Azathioprine; Bacterial Infections; Bone Marrow; Cardiovascular Disease | 1982 |
Conversion from cyclosporin to azathioprine after kidney transplantation.
Topics: Apolipoproteins A; Azathioprine; Cardiovascular Diseases; Cyclosporine; Drug Therapy, Combination; H | 1995 |
[After care following kidney transplantation].
Topics: Adrenal Cortex Hormones; Azathioprine; Cardiovascular Diseases; Cyclosporine; Drug Therapy, Combinat | 1994 |
Post-transplant conversion from cyclosporin to azathioprine: effect on cardiovascular risk profile.
Topics: Adult; Azathioprine; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cyclosporine; Female; Gra | 1993 |
Cyclosporine and lipid peroxidation.
Topics: Azathioprine; Cardiovascular Diseases; Cyclosporine; Humans; Immunosuppressive Agents; Kidney Transp | 1998 |
Acquired Factor VIII autoantibody: four cases demonstrating the heterogenous nature of this condition and problems involved in diagnosis and treatment.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Autoantibodies; Autoimmune Diseases; Azathiop | 2001 |
Cardiovascular risk impact of cyclosporine immunosuppression in renal transplant recipients.
Topics: Adult; Antihypertensive Agents; Azathioprine; Blood Pressure; Cardiovascular Diseases; Cause of Deat | 1992 |